Roivant Sciences (STU:87S) Net Change in Cash : €603.4 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Roivant Sciences's Net Change in Cash for the three months ended in Sep. 2024 was €-3,301.7 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was €603.4 Mil.

Roivant Sciences Net Change in Cash Historical Data

The historical data trend for Roivant Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Net Change in Cash Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Net Change in Cash

-107.16

-61.42

-356.71

4,469.67

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Change in Cash	Get a 7-Day Free Trial													-24.79	4,825.50	-124.21	-796.29	-3,301.65

Roivant Sciences Net Change in Cash Calculation

Roivant Sciences's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-704.047	+	4787.333	+	385.815	+	0.567
	=	4,469.7

Roivant Sciences's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -240.392 + -2967.528 + -98.276 + 4.544

= -3,301.7

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €603.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Roivant Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Net Change in Cash

Comparable Companies

EXEL IONS KRTX APLS JAZZ ABCZF ASND IMVT HALO PCVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ROIV:USA 87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines